Presentation

Company Profile
Iconovo develops ready-to-use inhalation products – inhalers and dry powder formulation. The products are used to treat asthma and chronic obstructive pulmonary disease (COPD), but the company also has the competence to develop products for new types of inhaled drugs such as vaccines. Iconovo licenses its patented products to global generic and pharmaceutical companies, thereby offering them a faster way to the inhalation market with lower risk and at lower cost. Iconovo was founded in 2013 and is based in Lund, Sweden.

Recent highlights
In March2021, Iconovo announced that it has signed an agreement with ISR for the development of inhaled COVID-19 vaccine IN Iconovo’s inhaler ICOone. In May, the company announced that its collaboration with the U.S. pharmaceutical company Amneal is expanding to include additional territories. On the same month, the company announced that it signed an agreement with Respiratorius for the development of an inhalation formulation as well as an inhalation product for phase I studies, for Respiratorius’ drug candidate RES030-085, indicated towards COPD. In July, the company completed a directed share issue of SEK 75 million, with the main intention being business development and sales expansion.

Outlook
Iconovo’s goal is to enter 1-3 new customer agreements per year, aiming towards sales of SEK 200 million and operating profit of SEK 100 million by 2026.